公开(公告)号：US20220378722A1

公开(公告)日：2022-12-01

申请号：US17661971

申请日：2022-05-04

Applicant: Oryzon Genomics, S.A.

Inventor： Mark D. DEMARIO ,  Tamara MAES ,  William E. PIERCEALL ,  Fiona MACK ,  Serena LUNARDI

IPC: A61K31/135 ,  A61K31/12 ,  A61K31/19 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4045 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/495 ,  A61K31/519 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7068 ,  A61K31/167 ,  A61K31/404 ,  A61K31/4402 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/496 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/551 ,  A61K31/635

Abstract: The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).

公开(公告)号：US20190153538A1

公开(公告)日：2019-05-23

申请号：US15766086

申请日：2016-10-08

Applicant: Oryzon Genomics, S.A.

Inventor： Wei-Yi CHENG ,  Mark D. DEMARIO ,  Fiona MACK ,  Francesca MILLETTI ,  William E. PIERCEALL

IPC: C12Q1/6886 ,  G16H50/30 ,  G16H50/20

Abstract: The present application discloses a method to predict responsiveness of a patient, with cancer, to treatment with LSD1 inhibitors, said method comprising measuring mRNA expression levels of one or more genes selected from the list of ASCL1, DDC, CEACAM6, LRRIQ4, NR0B2, GRP, CEACAM5, SOX21, OR51E2, SEC11C, BAALC, CCDC40, RAB3B, RGS17, ABCE1, ETS2, CCDC154, SPAG6, PON1, TMEM176A, C1orf127, IGF2BP2, IGFBP5, FAM84A, FOXA2, HOXA10, NCAM1, NCAM2, NEUROD1, KRT8, ENO2, AVP, OXT, SYP, CHGA, CHGB, BCL2 and MYC.

公开(公告)号：US20190256929A1

公开(公告)日：2019-08-22

申请号：US16346909

申请日：2017-11-02

Applicant: ORYZON GENOMICS, S.A.

Inventor： Fabian BIRZELE ,  Wei-Yi CHENG ,  Mark D. DEMARIO ,  Fiona MACK ,  Francesca MILLETTI ,  William E. PIERCEALL

IPC: C12Q1/6886 ,  G16H50/20 ,  G01N33/50

Abstract: The invention provides methods of monitoring differential gene expression of pharmacodynamic (PD) biomarkers in patients treated with Lysine Demethylase 1 (LSD 1) inhibitors and methods of determining the sensitivity of a cell to an LSD 1 inhibitor by measuring PD biomarkers.